• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    MannKind Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    11/5/25 8:03:50 AM ET
    $MNKD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MNKD alert in real time by email
    8-K
    false000089946000008994602025-11-052025-11-05

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): November 05, 2025

     

     

    MannKind Corporation

    (Exact name of Registrant as Specified in Its Charter)

     

     

    Delaware

    000-50865

    13-3607736

    (State or Other Jurisdiction
    of Incorporation)

    (Commission File Number)

    (IRS Employer
    Identification No.)

     

     

     

     

     

    1 Casper Street

     

    Danbury, Connecticut

     

    06810

    (Address of Principal Executive Offices)

     

    (Zip Code)

     

    Registrant’s Telephone Number, Including Area Code: (818) 661-5000

     

    N/A

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:


    Title of each class

     

    Trading
    Symbol(s)

     


    Name of each exchange on which registered

    Common Stock, par value $0.01 per share

     

    MNKD

     

    The Nasdaq Stock Market LLC

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     


    Item 2.02. Results of Operations and Financial Condition.

    On November 5, 2025, MannKind Corporation issued a press release, a copy of which is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.

    Item 9.01. Financial Statements and Exhibits.

     

    Exhibit 99.1

    Press release dated November 5, 2025

     

     

    Exhibit 104

    Cover Page Interactive Data File (embedded within the Inline XBRL document)

     


    SIGNATURE

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    MannKind Corporation

     

    Date: November 5, 2025

    By:

    /s/ David Thomson, Ph.D., J.D.

    David Thomson, Ph.D., J.D.

    Corporate Vice President, General Counsel and Secretary

     

     


    Get the next $MNKD alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MNKD

    DatePrice TargetRatingAnalyst
    11/13/2025$7.00Outperform
    Leerink Partners
    10/20/2025$10.00Overweight
    Wells Fargo
    10/10/2025$9.00Outperform
    Leerink Partners
    7/16/2025$9.00Buy
    H.C. Wainwright
    4/10/2025$12.00Outperform
    Mizuho
    2/10/2025$11.00Outperform
    Wedbush
    12/20/2024$9.00Overweight
    Wells Fargo
    12/19/2024$7.00 → $10.00Sector Perform → Outperform
    RBC Capital Mkts
    More analyst ratings

    $MNKD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Leerink Partners initiated coverage on Mannkind with a new price target

    Leerink Partners initiated coverage of Mannkind with a rating of Outperform and set a new price target of $7.00

    11/13/25 9:09:54 AM ET
    $MNKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wells Fargo initiated coverage on Mannkind with a new price target

    Wells Fargo initiated coverage of Mannkind with a rating of Overweight and set a new price target of $10.00

    10/20/25 8:01:49 AM ET
    $MNKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Leerink Partners initiated coverage on Mannkind with a new price target

    Leerink Partners initiated coverage of Mannkind with a rating of Outperform and set a new price target of $9.00

    10/10/25 8:38:42 AM ET
    $MNKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MNKD
    SEC Filings

    View All

    SEC Form 8-K filed by MannKind Corporation

    8-K - MANNKIND CORP (0000899460) (Filer)

    11/10/25 8:05:14 AM ET
    $MNKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by MannKind Corporation

    10-Q - MANNKIND CORP (0000899460) (Filer)

    11/5/25 8:06:06 AM ET
    $MNKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MannKind Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - MANNKIND CORP (0000899460) (Filer)

    11/5/25 8:03:50 AM ET
    $MNKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MNKD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $MNKD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    EVP Technical Operations Singh Sanjay R sold $94,448 worth of shares (18,777 units at $5.03), decreasing direct ownership by 4% to 455,211 units (SEC Form 4)

    4 - MANNKIND CORP (0000899460) (Issuer)

    11/14/25 8:00:11 PM ET
    $MNKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Ahuja Ajay was granted 318,200 shares (SEC Form 4)

    4 - MANNKIND CORP (0000899460) (Issuer)

    11/12/25 8:00:03 PM ET
    $MNKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP Technical Operations Singh Sanjay R covered exercise/tax liability with 17,071 shares, decreasing direct ownership by 3% to 473,988 units (SEC Form 4)

    4 - MANNKIND CORP (0000899460) (Issuer)

    11/3/25 8:16:34 PM ET
    $MNKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MannKind to Present at the Jefferies Global Healthcare Conference

    DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Nov. 11, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) announced today that Michael Castagna, Chief Executive Officer, and Chris Prentiss, Chief Financial Officer, are scheduled to present and share updates during the Jefferies London Healthcare Conference on Wednesday, November 19, at 6:30 am ET/11:30 am GMT. The link to the live audio webcast of the session is available on MannKind Corporation's website at: https://investors.mannkindcorp.com/events-and-presentations. Recorded versions will also be available on the website for approximately 90 days following the conference. About MannKindMannKind Corporation (NASDAQ:MNKD) is a b

    11/11/25 4:05:00 PM ET
    $MNKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MannKind Provides Update on Phase 3 ICoN-1 Trial of Nebulized Clofazimine for NTM Lung Disease

    MannKind has made the decision to discontinue the ICoN-1 Phase 3 clinical trial evaluating nebulized clofazimine inhalation suspension for nontuberculous mycobacterial (NTM) lung disease, following a futility determination based on medical monitoring dataThis outcome does not impact the development of MNKD-102, MannKind's dry powder inhalation (DPI) formulation of clofazimine, which remains under consideration for future clinical advancementMannKind extends its sincere gratitude to the study participants, investigators, advisors, and clinical site teams for their invaluable contributions to the ICoN-1 studyMannKind will host a conference call today at 9:00 AM EST to discuss this update in mo

    11/10/25 8:00:00 AM ET
    $MNKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MannKind Corporation Reports Third Quarter 2025 Financial Results and Provides Business Update

    Q3 2025 revenues of $82.1M, +17% v. Q3 2024YTD 2025 revenues of $237.0M, +14% v. YTD 2024Completed acquisition of scPharmaceuticals on October 7, accelerating MannKind's revenue growth with FUROSCIX®Program updates: sBLA for Afrezza® in pediatric population accepted for FDA review; PDUFA date of May 29, 2026FUROSCIX ReadyFlow™ Autoinjector sNDA submitted to the FDA MNKD-101 NTM global Phase 3 trial (ICoN-1) achieved interim enrollment target ahead of schedule MNKD-201 IPF Phase 2 trial (INFLO) initiated and expect to enroll first patient in Q1 2026 DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today re

    11/5/25 8:00:00 AM ET
    $MNKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MNKD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by MannKind Corporation (Amendment)

    SC 13G/A - MANNKIND CORP (0000899460) (Subject)

    2/13/24 5:08:11 PM ET
    $MNKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by MannKind Corporation (Amendment)

    SC 13G/A - MANNKIND CORP (0000899460) (Subject)

    1/22/24 12:56:57 PM ET
    $MNKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by MannKind Corporation (Amendment)

    SC 13G/A - MANNKIND CORP (0000899460) (Subject)

    2/9/23 11:25:13 AM ET
    $MNKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MNKD
    Leadership Updates

    Live Leadership Updates

    View All

    MannKind Appoints Dr. Ajay Ahuja as Executive Vice President and Chief Medical Officer

    WESTLAKE VILLAGE, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, today announced the appointment of Ajay Ahuja, MD, MBA, as Chief Medical Officer, effective today. Dr. Ahuja will report directly to Michael Castagna, PharmD, Chief Executive Officer, and will serve on the company's executive leadership team. "Ajay's deep expertise in medical affairs, clinical development, and global strategy—combined with his background as a practicing physician—will be instrumental as we continue to advance o

    9/29/25 6:05:00 AM ET
    $MNKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MannKind Extends Collaboration With Thirona Bio on Fibrotic Lung Diseases

    MannKind purchased an additional convertible note issued by Thirona BioNonclinical PD study of MNKD-501 planned, with results anticipated in 2Q 2022MannKind's CEO appointed as a member of the Thirona board of directors DANBURY, Conn., Jan. 05, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced that has extended its collaboration with Thirona Bio, Inc. ("Thirona") with the purchase of a second convertible note issued by Thirona, and the appointment of Michael Castagna, PharmD as a member of the Thirona board of directors.

    1/5/22 6:05:00 AM ET
    $MNKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MNKD
    Financials

    Live finance-specific insights

    View All

    MannKind Provides Update on Phase 3 ICoN-1 Trial of Nebulized Clofazimine for NTM Lung Disease

    MannKind has made the decision to discontinue the ICoN-1 Phase 3 clinical trial evaluating nebulized clofazimine inhalation suspension for nontuberculous mycobacterial (NTM) lung disease, following a futility determination based on medical monitoring dataThis outcome does not impact the development of MNKD-102, MannKind's dry powder inhalation (DPI) formulation of clofazimine, which remains under consideration for future clinical advancementMannKind extends its sincere gratitude to the study participants, investigators, advisors, and clinical site teams for their invaluable contributions to the ICoN-1 studyMannKind will host a conference call today at 9:00 AM EST to discuss this update in mo

    11/10/25 8:00:00 AM ET
    $MNKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MannKind Corporation Reports Third Quarter 2025 Financial Results and Provides Business Update

    Q3 2025 revenues of $82.1M, +17% v. Q3 2024YTD 2025 revenues of $237.0M, +14% v. YTD 2024Completed acquisition of scPharmaceuticals on October 7, accelerating MannKind's revenue growth with FUROSCIX®Program updates: sBLA for Afrezza® in pediatric population accepted for FDA review; PDUFA date of May 29, 2026FUROSCIX ReadyFlow™ Autoinjector sNDA submitted to the FDA MNKD-101 NTM global Phase 3 trial (ICoN-1) achieved interim enrollment target ahead of schedule MNKD-201 IPF Phase 2 trial (INFLO) initiated and expect to enroll first patient in Q1 2026 DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today re

    11/5/25 8:00:00 AM ET
    $MNKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MannKind Corporation to Hold 2025 Third Quarter Financial Results Conference Call on November 5, 2025

    DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), announced today that its third quarter 2025 financial results will be released before the market opens on November 5, 2025. MannKind will host a webcast beginning at 9 a.m. Eastern Time to discuss the financial results and provide a business update. The webcast will be accessible via a link on MannKind's website at https://investors.mannkindcorp.com/events-and-presentations. A replay will also be available in the same location within 24 hours following the call and be accessible for approximately 90 days. About MannKindMannKind Corporation (NASDAQ:MNKD) is a biopharmaceutica

    10/29/25 4:05:00 PM ET
    $MNKD
    Biotechnology: Pharmaceutical Preparations
    Health Care